Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

How to Choose the Right Inducible Gene Expression System for Mammalian Studies?

Kallunki T, Barisic M, Jäättelä M, Liu B.

Cells. 2019 Jul 30;8(8). pii: E796. doi: 10.3390/cells8080796. Review.

2.

Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion.

Brix DM, Tvingsholm SA, Hansen MB, Clemmensen KB, Ohman T, Siino V, Lambrughi M, Hansen K, Puustinen P, Gromova I, James P, Papaleo E, Varjosalo M, Moreira J, Jäättelä M, Kallunki T.

Oncogene. 2019 Apr;38(17):3170-3184. doi: 10.1038/s41388-018-0653-x. Epub 2019 Jan 8.

3.

Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1.

Tvingsholm SA, Hansen MB, Clemmensen KKB, Brix DM, Rafn B, Frankel LB, Louhimo R, Moreira J, Hautaniemi S, Gromova I, Jäättelä M, Kallunki T.

Oncogenesis. 2018 Feb 3;7(2):14. doi: 10.1038/s41389-017-0014-6.

4.

The Mutational Landscape of the Oncogenic MZF1 SCAN Domain in Cancer.

Nygaard M, Terkelsen T, Vidas Olsen A, Sora V, Salamanca Viloria J, Rizza F, Bergstrand-Poulsen S, Di Marco M, Vistesen M, Tiberti M, Lambrughi M, Jäättelä M, Kallunki T, Papaleo E.

Front Mol Biosci. 2016 Dec 15;3:78. doi: 10.3389/fmolb.2016.00078. eCollection 2016.

5.

Screening and identification of small molecule inhibitors of ErbB2-induced invasion.

Brix DM, Rafn B, Bundgaard Clemmensen K, Andersen SH, Ambartsumian N, Jäättelä M, Kallunki T.

Mol Oncol. 2014 Dec;8(8):1703-18. doi: 10.1016/j.molonc.2014.07.004. Epub 2014 Jul 12.

6.

S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells.

Jaiswal JK, Lauritzen SP, Scheffer L, Sakaguchi M, Bunkenborg J, Simon SM, Kallunki T, Jäättelä M, Nylandsted J.

Nat Commun. 2014 May 8;5:3795. doi: 10.1038/ncomms4795.

7.

When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.

Brix DM, Clemmensen KK, Kallunki T.

Cells. 2014 Jan 27;3(1):53-78. doi: 10.3390/cells3010053.

8.

ErbB2 upregulates the Na+,HCO3(-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4.

Gorbatenko A, Olesen CW, Mørup N, Thiel G, Kallunki T, Valen E, Pedersen SF.

FASEB J. 2014 Jan;28(1):350-63. doi: 10.1096/fj.13-233288. Epub 2013 Oct 2.

PMID:
24088818
9.

Cancer-associated lysosomal changes: friends or foes?

Kallunki T, Olsen OD, Jäättelä M.

Oncogene. 2013 Apr 18;32(16):1995-2004. doi: 10.1038/onc.2012.292. Epub 2012 Jul 9. Review.

PMID:
22777359
10.

A way to invade: a story of ErbB2 and lysosomes.

Rafn B, Kallunki T.

Cell Cycle. 2012 Jul 1;11(13):2415-6. doi: 10.4161/cc.20860. Epub 2012 Jul 1. No abstract available.

11.

ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.

Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, Valo E, Fehrenbacher N, Olsen CJ, Daugaard M, Egebjerg C, Bøttzauw T, Kohonen P, Nylandsted J, Hautaniemi S, Moreira J, Jäättelä M, Kallunki T.

Mol Cell. 2012 Mar 30;45(6):764-76. doi: 10.1016/j.molcel.2012.01.029.

12.

Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.

Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, Daugaard M, Valo E, Tuomela S, Bøttzauw T, Nielsen CF, Willumsen BM, Hautaniemi S, Lahesmaa R, Westermarck J, Jäättelä M, Kallunki T.

Oncogene. 2012 Jan 19;31(3):390-401. doi: 10.1038/onc.2011.230. Epub 2011 Jun 27.

PMID:
21706057
13.

A comprehensive siRNA screen for kinases that suppress macroautophagy in optimal growth conditions.

Szyniarowski P, Corcelle-Termeau E, Farkas T, Høyer-Hansen M, Nylandsted J, Kallunki T, Jäättelä M.

Autophagy. 2011 Aug;7(8):892-903. Epub 2011 Aug 1.

PMID:
21508686
14.

Phosphorylation of SCG10/stathmin-2 determines multipolar stage exit and neuronal migration rate.

Westerlund N, Zdrojewska J, Padzik A, Komulainen E, Björkblom B, Rannikko E, Tararuk T, Garcia-Frigola C, Sandholm J, Nguyen L, Kallunki T, Courtney MJ, Coffey ET.

Nat Neurosci. 2011 Mar;14(3):305-13. doi: 10.1038/nn.2755. Epub 2011 Feb 6.

PMID:
21297631
15.

Loss-of-function of IKAP/ELP1: could neuronal migration defect underlie familial dysautonomia?

Naumanen T, Johansen LD, Coffey ET, Kallunki T.

Cell Adh Migr. 2008 Oct-Dec;2(4):236-9. Epub 2008 Oct 17.

16.

Identification of nucleolar effects in JNK-deficient cells.

Mialon A, Thastrup J, Kallunki T, Mannermaa L, Westermarck J, Holmström TH.

FEBS Lett. 2008 Sep 3;582(20):3145-51. doi: 10.1016/j.febslet.2008.08.004. Epub 2008 Aug 12.

17.

Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2.

Fehrenbacher N, Bastholm L, Kirkegaard-Sørensen T, Rafn B, Bøttzauw T, Nielsen C, Weber E, Shirasawa S, Kallunki T, Jäättelä M.

Cancer Res. 2008 Aug 15;68(16):6623-33. doi: 10.1158/0008-5472.CAN-08-0463.

18.

IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration.

Johansen LD, Naumanen T, Knudsen A, Westerlund N, Gromova I, Junttila M, Nielsen C, Bøttzauw T, Tolkovsky A, Westermarck J, Coffey ET, Jäättelä M, Kallunki T.

J Cell Sci. 2008 Mar 15;121(Pt 6):854-64. doi: 10.1242/jcs.013722. Epub 2008 Feb 26.

19.

CIP2A inhibits PP2A in human malignancies.

Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J.

Cell. 2007 Jul 13;130(1):51-62.

20.

c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1.

Nielsen C, Thastrup J, Bøttzauw T, Jäättelä M, Kallunki T.

Cancer Res. 2007 Jan 1;67(1):178-85.

21.

Depletion of the AP-1 repressor JDP2 induces cell death similar to apoptosis.

Lerdrup M, Holmberg C, Dietrich N, Shaulian E, Herdegen T, Jäättelä M, Kallunki T.

Biochim Biophys Acta. 2005 Aug 15;1745(1):29-37.

22.

Constitutively active cytoplasmic c-Jun N-terminal kinase 1 is a dominant regulator of dendritic architecture: role of microtubule-associated protein 2 as an effector.

Björkblom B, Ostman N, Hongisto V, Komarovski V, Filén JJ, Nyman TA, Kallunki T, Courtney MJ, Coffey ET.

J Neurosci. 2005 Jul 6;25(27):6350-61.

23.

Sensitization to the lysosomal cell death pathway upon immortalization and transformation.

Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, Weber E, Leist M, Jäättelä M.

Cancer Res. 2004 Aug 1;64(15):5301-10.

24.

JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways.

Dietrich N, Thastrup J, Holmberg C, Gyrd-Hansen M, Fehrenbacher N, Lademann U, Lerdrup M, Herdegen T, Jäättelä M, Kallunki T.

Cell Death Differ. 2004 Mar;11(3):301-13.

25.

A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling.

Holmberg C, Katz S, Lerdrup M, Herdegen T, Jäättelä M, Aronheim A, Kallunki T.

J Biol Chem. 2002 Aug 30;277(35):31918-28. Epub 2002 Jun 10.

28.

c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation.

Sabapathy K, Kallunki T, David JP, Graef I, Karin M, Wagner EF.

J Exp Med. 2001 Feb 5;193(3):317-28.

29.
30.
31.

JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development.

Sabapathy K, Hu Y, Kallunki T, Schreiber M, David JP, Jochum W, Wagner EF, Karin M.

Curr Biol. 1999 Feb 11;9(3):116-25.

32.

Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases.

Jäättelä M, Wissing D, Kokholm K, Kallunki T, Egeblad M.

EMBO J. 1998 Nov 2;17(21):6124-34.

33.

Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury.

Herdegen T, Claret FX, Kallunki T, Martin-Villalba A, Winter C, Hunter T, Karin M.

J Neurosci. 1998 Jul 15;18(14):5124-35.

34.

c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions.

Kallunki T, Deng T, Hibi M, Karin M.

Cell. 1996 Nov 29;87(5):929-39.

35.

In vivo association of ATFa with JNK/SAP kinase activities.

Bocco JL, Bahr A, Goetz J, Hauss C, Kallunki T, Kedinger C, Chatton B.

Oncogene. 1996 May 2;12(9):1971-80.

PMID:
8649858
36.

Structure of the human laminin gamma 2 chain gene (LAMC2): alternative splicing with different tissue distribution of two transcripts.

Airenne T, Haakana H, Sainio K, Kallunki T, Kallunki P, Sariola H, Tryggvason K.

Genomics. 1996 Feb 15;32(1):54-64.

PMID:
8786121
37.

JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation.

Kallunki T, Su B, Tsigelny I, Sluss HK, Dérijard B, Moore G, Davis R, Karin M.

Genes Dev. 1994 Dec 15;8(24):2996-3007.

38.

JNK is involved in signal integration during costimulation of T lymphocytes.

Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y.

Cell. 1994 Jun 3;77(5):727-36.

PMID:
8205621
39.

A truncated laminin chain homologous to the B2 chain: structure, spatial expression, and chromosomal assignment.

Kallunki P, Sainio K, Eddy R, Byers M, Kallunki T, Sariola H, Beck K, Hirvonen H, Shows TB, Tryggvason K.

J Cell Biol. 1992 Nov;119(3):679-93.

40.

Structure of the human laminin B2 chain gene reveals extensive divergence from the laminin B1 chain gene.

Kallunki T, Ikonen J, Chow LT, Kallunki P, Tryggvason K.

J Biol Chem. 1991 Jan 5;266(1):221-8.

41.

A Pst I polymorphism in the human laminin B2 chain gene on 1q25-q31.

Kallunki T, Pikkarainen T, Tryggvason K, Savolainen ER.

Nucleic Acids Res. 1989 Jun 12;17(11):4423. No abstract available.

43.

Isolation of a human laminin B2 (LAMB2) cDNA clone and assignment of the gene to chromosome region 1q25----q31.

Fukushima Y, Pikkarainen T, Kallunki T, Eddy RL, Byers MG, Haley LL, Henry WM, Tryggvason K, Shows TB.

Cytogenet Cell Genet. 1988;48(3):137-41.

PMID:
3234037

Supplemental Content

Loading ...
Support Center